HSC Exam Practice

Sample response. Active immunity is immunity produced when an individual’s own immune system mounts a response to an antigen — through either natural infection or vaccination — resulting in clonal selection, plasma cell antibody production, and the formation of long-lived memory B and T cells. Passive immunity, by contrast, involves the receipt of pre-formed antibodies from an external source (maternal transfer or injection). Because the recipient’s own lymphocytes are not activated in passive immunity, no memory cells are formed, and protection is temporary (weeks to months) rather than long-lasting.

Marking notes. 1 mark: active immunity correctly defined as own immune system responding to antigen, forming memory cells. 1 mark: passive immunity correctly defined as receiving pre-formed antibodies without activating own immune system. 1 mark: explicit contrast on memory-cell formation (active = yes; passive = no), with consequence for duration stated.

Sample response. Natural passive immunity: maternal IgG antibodies transferred across the placenta from a pregnant mother to the foetus. The antibodies are produced by the mother’s own immune system and pass to the foetus by active transport across the placental barrier. Protection is temporary because the infant’s own immune system is never activated; the received antibodies are catabolised over approximately 3–6 months and no memory B cells are formed. Artificial passive immunity: antivenom administered to a snakebite victim (e.g. CSL polyvalent antivenom for eastern brown snake envenomation in Australia). The antibodies are produced in immunised animals (horses or sheep); they are harvested, purified, and injected as a medical intervention. Protection is temporary for the same reason: the patient’s own immune system does not mount a response, no memory cells are formed, and the foreign antibodies are gradually catabolised.

Marking notes. Natural passive: 1 mark for named correct example with antibody source identified; 1 mark for correct mechanism of why temporary (no memory cells; antibodies catabolised). Artificial passive: 1 mark for named correct example with antibody source identified; 1 mark for correct mechanism of why temporary (same reasoning). Accept IgA via breast milk as a second correct natural passive example. Accept immunoglobulin injection (IVIG, anti-D) as artificial passive alternative.

Sample response. Herd immunity occurs when a sufficient proportion of a population is immune to a pathogen — through vaccination or prior infection — such that transmission chains cannot be sustained and even susceptible, unvaccinated individuals are indirectly protected. The herd immunity threshold — the minimum proportion of the population that must be immune — is determined by the pathogen’s R&sub0; (basic reproduction number), using the formula: threshold = 1 − (1/R&sub0;). A higher R&sub0; means each infected person infects more people in a fully susceptible population, so a larger proportion of the population must be immune to prevent sustained spread. For example: measles (R&sub0; ≈ 12–18) requires ~93–95% immunity; polio (R&sub0; ≈ 5–7) requires ~80–85%.

Marking notes. 1 mark: herd immunity correctly defined as sufficient immunity breaking transmission chains and protecting susceptible individuals. 1 mark: threshold determined by R&sub0; via formula threshold = 1 − 1/R&sub0; (formula stated or applied). 1 mark: correct explanation that higher R&sub0; = higher threshold, supported by one named example with approximate figures.

Sample response. Elimination is the reduction of disease incidence to zero in a defined geographic area, while the pathogen still exists elsewhere in the world. Eradication is the permanent global reduction to zero — the pathogen no longer exists in nature anywhere. Smallpox is the only human disease to have been eradicated: declared globally eradicated by the WHO in 1980 after a coordinated worldwide vaccination campaign; the virus only exists in two high-security laboratories. Measles has been eliminated from Australia (no sustained local transmission for defined periods) but not eradicated; the measles virus still circulates globally, and unvaccinated travellers returning from overseas regularly re-introduce cases, which can spark outbreaks if local vaccination coverage falls below ~95%.

Marking notes. 1 mark: elimination correctly defined as zero local transmission in a defined area, pathogen still exists elsewhere. 1 mark: eradication correctly defined as permanent global zero — pathogen no longer exists in nature. 1 mark: smallpox and measles correctly applied (smallpox = eradicated 1980 globally; measles = eliminated in Australia but not globally, with importation risk).

Sample response. Smallpox was eradicated because it had no animal reservoir (humans were the only host), was easily identifiable by visible symptoms, had a stable antigen not subject to rapid mutation, and a highly effective, stable vaccine. Influenza lacks all of these favourable conditions. First, influenza has a large animal reservoir: influenza A viruses circulate endemically in wild birds (aquatic birds are the primary reservoir) and pigs. Even if all human influenza were eliminated, novel influenza strains would continue to emerge from animal reservoirs through reassortment and zoonotic transfer into human populations — as occurred with H1N1 in 2009, H5N1 (avian influenza), and earlier pandemic strains. Second, influenza undergoes rapid antigenic variation through two distinct mechanisms: antigenic drift (accumulation of point mutations in haemagglutinin and neuraminidase surface proteins, making the virus slightly different each season) and antigenic shift (reassortment of genome segments between different influenza A strains, producing pandemic viruses with entirely novel surface antigens). Immunity acquired to one influenza strain — through infection or vaccination — may provide little protection against a new strain with different surface antigens, meaning the vaccine must be reformulated annually and no stable long-term herd immunity can be built in a population against all circulating strains simultaneously.

Marking notes. 1 mark: correctly identifies and explains animal reservoir (bird/pig) as a barrier — influenza would re-emerge from animals even if human strains were eliminated. 1 mark: correctly identifies and explains rapid antigenic variation (drift and/or shift) as a barrier — existing immunity does not protect against new strains. 1 mark: explicitly contrasts with smallpox on at least one of these features (e.g. “unlike smallpox, influenza has a large animal reservoir”). 1 mark: explains consequence of antigenic variation for vaccination programs (must be reformulated annually; herd immunity cannot be maintained as vaccine and circulating strains diverge).

Sample response (a). Between 2005 and 2010, pertussis notifications showed a dramatic outbreak pattern: rising from approximately 20 per 100,000 in 2005, peaking at approximately 175 per 100,000 in 2009, then falling sharply to approximately 35 per 100,000 in 2010. During 2007–2009, vaccination coverage hovered around 90–91%, which is below the pertussis herd immunity threshold of ~92%. When population immunity drops below the threshold, the effective reproduction number rises above 1 — each case generates more than one new case — and transmission chains can sustain and amplify. The outbreak peaked when susceptible individuals (particularly those who had never been vaccinated, whose immunity had waned, or whose vaccine had not produced a full response) represented a large enough proportion of the population to support rapid spread.

Sample response (b). As coverage rose from 92% to 95% between 2011 and 2014, it crossed and moved consistently above the pertussis herd immunity threshold of ~92%. Once coverage exceeds the threshold, the effective reproduction number falls below 1: each new case generates, on average, fewer than one subsequent case, so transmission chains die out before spreading widely through the population. The dramatic reduction in notifications reflects this threshold effect: above the threshold, even susceptible individuals are indirectly protected because the pathogen cannot find enough susceptible hosts to sustain chains of transmission.

Sample response (c). Pertussis immunity — whether from natural infection or the current acellular pertussis vaccine (DTaP/dTpa) — wanes over time. Studies have shown that vaccine-induced immunity against pertussis can decline substantially within 4–12 years. This means that even in adults who were vaccinated as children, immunity may have fallen below a protective level, creating a pool of partially susceptible adults who can transmit to unvaccinated infants. Additionally, Bordetella pertussis has shown some evidence of genetic adaptation to the acellular vaccine (mutations in pertactin antigen, a key vaccine component). These two factors — waning immunity and potential antigenic adaptation — mean that high childhood coverage does not eliminate transmission entirely, as the adult population maintains a reservoir of susceptibility.

Marking notes (a). 1 mark: describes trend correctly including peak (~175/100,000 in 2009) and subsequent fall; 1 mark: links 2008–2009 spike to coverage falling below the 92% herd immunity threshold with correct reasoning (effective R above 1, transmission chains sustained). Part (b): 1 mark: rising coverage crossed and exceeded the ~92% threshold; 1 mark: above threshold, effective R falls below 1 — transmission chains die out; 1 mark: explains the threshold effect on notifications (dramatic reduction rather than gradual). Part (c): any one valid biological reason earns 3 marks: waning immunity from acellular vaccine (1 mark for identifying; 1 mark for consequence = susceptible adult pool; 1 mark for connecting to ongoing transmission). OR: bacterial adaptation/antigenic change with equivalent reasoning. Accept other valid biological barriers.

Sample response (a). Threshold = 1 − (1/R&sub0;) = 1 − (1/6) = 1 − 0.167 = 0.833 = 83.3%. At R&sub0; = 6, approximately 83% of the population must be immune to maintain herd immunity against rubella.

Sample response (b). Current coverage of 84% is marginally above the calculated threshold of 83.3% (using R&sub0; = 6), so in theory herd immunity should just be maintained. However, if actual vaccine effectiveness is less than 100%, or if coverage is unevenly distributed across communities (some clusters below 83%), the effective immunity in those clusters may fall below the local threshold, enabling localised outbreaks even when national coverage appears sufficient. The practical recommendation would be to increase coverage above 90% to provide a safety margin, particularly because rubella in pregnant women can cause congenital rubella syndrome in the foetus.

Sample response (c). New threshold = 1 − (1/9) = 1 − 0.111 = 0.889 = 88.9%. Current coverage of 84% would not be sufficient for a strain with R&sub0; = 9 — the country would be below the new threshold and outbreaks would become more likely. Antigenic change (e.g. mutations in surface proteins that vaccines target) can reduce the effectiveness of existing vaccines against new strains: if antibodies generated by the original vaccine bind less effectively to the new strain’s antigens, fewer vaccinated individuals are fully protected, effectively reducing the proportion of the truly immune population even when nominal coverage remains unchanged. This forces a re-evaluation of threshold and vaccine formulation.

Marking notes (a). 1 mark: correct formula applied (threshold = 1 − 1/R&sub0;) with R&sub0; = 6; 1 mark: correct answer of 83.3% (accept 83%). Part (b): 1 mark: correctly assesses 84% as marginally sufficient at R&sub0; = 6 but identifies the practical risk from uneven distribution or vaccine non-responders. Part (c): 1 mark: correct new threshold calculation (88.9% or 89%); 1 mark: correctly states 84% is insufficient at the new threshold; 1 mark: explains mechanism by which antigenic change undermines established vaccine programs (reduced antibody binding → effectively lower true immune proportion).

Sample response. Vaccination programs aim to build active immunity at sufficient population scale to achieve herd immunity — and understanding both the mechanism of active immunity and the precise threshold required for herd immunity is essential for designing programs that are actually effective rather than merely partially protective. Active immunity — whether from natural infection or vaccination — involves the recipient’s own immune system mounting a response to antigen, undergoing clonal selection, and producing memory B and T cells that persist for years to decades. This is the only type of immunity that sustains herd protection at population level: passive immunity (natural maternal transfer or injected immunoglobulin/antivenom) provides immediate but short-lived protection to the recipient without activating their own immune system, and cannot be conferred to the whole population through a vaccination program. Public health decisions must therefore focus on generating sufficient active immunity in enough people.

The herd immunity threshold directly determines what “enough people” means, and it varies profoundly between diseases according to their R&sub0;. For measles (R&sub0; ≈ 12–18), the threshold is ~95%: a vaccination program that achieves only 90% coverage will be insufficient, and the lesson data demonstrates this precisely — when Australian measles coverage fell below 95%, cases spiked dramatically from near zero to hundreds of cases within two years. Australia’s measles vaccination program (two-dose MMR schedule) has historically maintained coverage near 95%, achieving elimination — zero local transmission — though not global eradication, which requires worldwide zero. For polio (R&sub0; ≈ 5–7, threshold ~80–85%), the global eradication initiative has reduced cases from 350,000 per year in 1988 to fewer than 20 in 2024 by achieving and sustaining high coverage worldwide. Poliovirus has been eliminated from all countries except Pakistan and Afghanistan — not because the vaccine failed, but because geopolitical barriers (conflict, misinformation) prevent achieving threshold coverage in those regions.

These examples reveal two key public health principles. First, vaccination coverage targets must be set at or above the disease-specific herd immunity threshold — not at an arbitrary “high” coverage — because the threshold represents the point at which the pathogen’s effective reproduction number falls below 1. Even a few percentage points of under-coverage relative to the threshold can allow outbreaks to reignite. Second, passive immunity cannot substitute for active immunity at population level: the decision to recommend maternal pertussis vaccination in Australia during pregnancy is designed to confer natural passive immunity (maternal IgG) to newborns in the brief window before they can receive their own DTaP course at six weeks — a bridge strategy that acknowledges passive immunity’s temporary nature rather than a substitute for building active immunity in the child. Similarly, antivenom for snakebite is artificial passive immunity: effective immediately but temporary, appropriate for post-exposure emergency treatment, not for population-level prevention. Overall, effective vaccination programs must (a) generate durable active immunity via an immunologically appropriate vaccine formulation, (b) achieve and maintain coverage at or above the pathogen-specific herd immunity threshold, and (c) recognise that passive immunity strategies, while valuable in specific clinical contexts, cannot replace active immunity programs as the mechanism for breaking population transmission.

Marking notes. 1 mark — correctly defines active immunity (own immune system, memory cells formed, long-lasting) and distinguishes from passive immunity (pre-formed antibodies, no memory cells, temporary). 1 mark — correctly explains why only active immunity can sustain population-level herd immunity (passive is temporary and cannot be scaled across a population). 1 mark — correctly applies herd immunity threshold concept: threshold = 1 − 1/R&sub0;; higher R&sub0; requires higher threshold. 1 mark — names and applies at least one disease example (measles: R&sub0; 12–18, threshold ~95%, Australia near-eliminated) with quantitative or qualitative data. 1 mark — names and applies a second distinct disease example (polio: R&sub0; 5–7, threshold ~80–85%, near-eradicated globally) with data. 1 mark — makes a clear public health decision recommendation derived from threshold analysis (e.g. coverage targets must meet or exceed disease-specific threshold; even small drops below threshold allow outbreaks). 1 mark — integrates the active/passive distinction into a practical public health context (e.g. maternal pertussis vaccination as bridge passive immunity; antivenom as post-exposure passive treatment) showing nuanced understanding of when each type is appropriate. 1 mark — achieves a coherent overall analysis that synthesises both the immunity mechanism distinction AND the threshold concept into an integrated argument about vaccination program design, reaching an explicit analytical conclusion.